You are on page 1of 21

ANIM

A
MAL
L
A MAL
ANIM
L

HE
EALT
THC
CARE
E
Sec
ctoral Reporrt, 200
09

National Insttitute of Agricultural Exte


ension M
Managem
ment (MA
ANAGE)
Hyde
erabad

Contents

GENERAL PHARMACEUTICAL INDUSTRYS OVERVIEW:

3-4

Market size
Major players
Exports
ANIMAL HEALTH CARE:

4-6

Market size
Major players
SEGMENTATION:

7-9

Based on species
Based on products
MARKET COMPOSITION

10-14

MARKET DRIVERS

15-16

STRATEGIES TO TAP ANIMAL HEALTH CARE INDUSTRY

16-17

CHALLENGES

17

OPPORTUNITIES

18

OUTSORCING AS AN OPPORTUNITY

19-21

-Big Pharmaceuticals
-Mid-Sized Pharmaceuticals

FUTURE

21

Page|2

Industry Overview

The Indian pharmaceutical industry is a success story providing employment for millions
and ensuring that essential drugs at affordable prices are available to the vast population of
this sub-continent.
Richard

Gerster

The Indian Pharmaceutical Industry today is in the front rank of Indias science-based
industries with wide ranging capabilities in the complex field of drug manufacture and
technology. India stands at the 4th position in terms of volume (8% of world's production),
13th in terms of value, and 17th in terms of pharmaceutical export value in the global
pharmaceutical industry.
Market Size
Indian Pharmaceutical Industry is estimated to be worth 34,000 crore, growing at about a
CAGR of 8 to 9 percent. Indian pharmaceutical industry is expected to reach the value of
US$ 12 billion by the year 2010. The domestic market of Indian pharmaceutical is expected
to grow at rate of 12-13%. Drug sales to retail consumers grew by 9.8% to $6.98bn (34,000
crore) in the calendar year 2008, according to research firm ORG IMS research.
The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered
units. The market is highly fragmented with only 300 companies being in the organised
sector and controlling 70% of the market with market leader holding nearly 7% of the market
share. It is an extremely fragmented market with severe price competition and government
price control.
Major Players
The domestic pharmaceutical market is quite fragmented with the top five companies
commanding only 22% market share. Cipla Ltd has become the largest and the fastest
growing company among the top five companies, outclassing Ranbaxy Laboratories Ltd.
Even the top 20 companies have a total market share of about 57% only in contrast to the
global drug market dominated by the 10 largest companies that account for about 40% of
global sales.
Page|3

Indias domestic pharmaceutical industry(12 months year ended 2009)


Company

Size($ billion)

Market share(%)

Growth rate(%)

Total Pharma Market

6.9

100

9.9

Cipla

.36

5.3

13.4

Ranbaxy

.34

5.0

11.5

Galaxo Smithkline

.29

4.3

-1.2

Piramal health care

.27

3.9

11.7

Zydus cadilla

.24

3.6

6.8

Total top 5

1.53

22.1

Animal Health Care Industry


Indias livestock population is among the highest in the world. The livestock sector
contributes 4% to the GDP and 27% to the agriculture GDP. In addition to providing
nutritional security to the poor, it provides employment to millions in the rural areas.
The multi-billion veterinary health products market, though smaller in Opportunity as
compared with the human health sector, offers significant return on investment, primarily
driven by lower risk and faster product development cycles. The veterinary health products
market has remained resilient over the economic downturns of the past 2 decades.
Market Size
Globally the animal health industry in 2008 was valued at $19.2 billion with a nominal
growth of 7.2% and a real growth of 2.8%. In comparison the animal health industry in
India is worth 1200 crores in comparison to the pharmaceutical industry of worth 34000
crores. Increasing growth in demand and supply of products is one reason why there is
drastic change in size of Indian animal healthcare market.
More than 85% of global animal health sales are generated in 15 major markets.The
dominant sectors served by the Animal Health Product industry are cattle, poultry,
aquaculture and small ruminants. Pets, equine and others are comparatively insignificant
contributors whereas in countries like US the contribution of companion animals towards
animal health product industry is up to 37%.
Page|4

Market Structure
The structure of individual markets varies widely, reflecting a combination of factors such as
climate, the prevalence of particular animal diseases and the relative importance of individual
species to national livestock agriculture. Products for use in companion animals are
responsible for over half of all sales in some developed markets such as the US and UK, but
generate less than 5% of sales in emerging markets such as China and India, for example.
The US will remain the animal health industry's main growth engine, with sales to rise at a
compound annual rate of 5%. The US will be responsible for 40% of global market growth,
and will reach a value of US$8 billion by 2010. China will cement its position as the world's
second largest market for animal health products, while Brazil will replace France as the
sector's third biggest market.

Major Players
One of the silent contributors to the balance sheets of some Indian pharmaceutical companies
is the animal healthcare market. Off late, for a variety of reasons, there has been a paradigm
shift from being a silent player to a more aggressive positioning.
In India
Zydus Cadila
Alembic
Vetnex
Virbac Animal Health India
Intas Pharmaceuticals
Intervet India
Concept Pharmaceuticals
Wockhardt

Page|5

Generic Market In Animal Health Care Industry

threat of new entrants-2nd tier


companies, local companies

customer bargaining power-strong as


customer segment that comprises of
distributors and wholesalers is
consolidated

industry competition
intensely competetive
and highly fragmented

supplier bargaining in this industry


will remain low

threat from substitutes-authorised


generics, self generics

Globally the major names in this industry comprises of:


Pfizer
Merial
Schering Plough
DSM Nutritional Products
BASF Animal Nutrition
Bayer Animal Health
Elanco
Novartis
Ceva Sante.

Page|6

Segmen
ntation Bassed On Speccies

Livesttock
Annimal Health
H
C
Care

Comp
panion
n Animaals
Poulttry

Poultryy
t
India iss worlds 4th
largest prroducer of eggs and 5th largest broiler prodducer. The poultry

industryy is estimateed to have grown


g
at a rate
r of 13%
% per annum
m (from 1996 onwards) and has
outpaceed countryss GDP grow
wth rate off 9% as per Rabo bankk report on poultry ind
dustry in
2008. The
T poultry industry is estimated at 40,000 crore
c
accordding to minister of agriculture,
GOI prooduction is estimated at
a around 2.6 million to
onne of pouultry meat aand 47 billio
on eggs.
India prroduces 2 billion
b
poulltry birds att 200,000 farms.
fa
Howeever, the w
wet market accounts
a
for 95%
% of Indian poultry
p
meaat industry sales.
s
Meat Production
P
I India
In
Year

Prod
duction( million
m
tonne)

2003-044

2.1

2004-055

2.2

2005-066

2.3

2006-077

2.3

2007-088

2.6

Source:: Indiaagristtat.com

Page|7

Poultry contributes a huge share of 38% of the animal health care market. In poultry, growth
is mainly projected in segments like pelleted feeds, vitamin premix and fed additives like
enzymes, pro-biotic, toxin binders, amino acids and coccidiostat.
Livestock
The ""livestock"" segment, a high-volume market that represents around 57% of the
international animal health market is guided mostly by economic concerns as the market has
to meet the growing demand in protein requirements in developing countries. Increase in
demand for protein inevitably leads to increase in demand for food-producing animals.
The cattle population for CY 2009 is forecast at 281.4 million head, continuing the multiyear
declining trend. However, the decline is specific to the cow population only and not to
buffalo population. The production of milk in India has been estimated as 104 million tonne
for the year 2008 in comparison to the world production of 684 million tonne (as per Indian
dairy association). Post forecasts, the CY beef production up by 4.5 percent to 2.7 million
tons (USDA FAS Livestock and Products Annual 2008 report) as it is cheapest compared to
all other meats. Demand for Indian buffalo meat is gradually growing in export markets due
to its cost competitiveness, perceived organic nature and proportion of less fat.
Companion Animals
Products for use in companion animals have been the main driver of growth in the world
market for veterinary pharmaceuticals and vaccines since the mid-1990s. Growth of the
global market for companion animal health products is forecasted at a compound annual rate
of 4.9% in the period to 2010 (at actual prices, and calculated at constant rates of exchange),
with sales in the sector reaching $8.6 billion in 2010.
The current overall size of Indian pet care and pet food market, in terms of current price
value, is Rs 1739.9 million, expecting to grow up to Rs 3,687.5 million by 2012. Of this, the
pet care segment occupies Rs 507.5 million. Pet care market accounts for all categories of
products ranging from toys to grooming products like shampoo, harnesses, collars, etc. Yearon-year average CGAR of pet shops in India accounts for 0.4 percent during 2002-07.
The common factors that will act as drivers or constraints on rates of growth in the
companion animal products market during the second half of this decade include companion
animal populations; economic, social and demographic trends; new products and
Page|8

technologies; promotion and marketing strategies; companion animal health and disease
trends; patent expiries and generic penetration of the companion animal products market;
product safety issues; regulatory factors; and companion animal health insurance.
In companion animal products, the market is relatively concentrated, with almost two-thirds
of global sales by value generated by ten leading companies. Merial is the outright market
leader, claiming a share of almost 17%, while Pfizer is its closest competitor with a 12%
share. Bayer, Novartis and Fort Dodge complete the top five rankings.
Indian leading pet care companies, which are predominantly sub-divisions of pharma majors,
are significantly contributing to the booming industry. Major players like Vetnex-RFCL,
PetCare, Venkys Pet, Intas, and Pfizer are potential boosters of the growing pet care market.
Their products, which are categorised from premium and super premium range, are widely
distributed all over India covering the countrys remotest regions.

Page|9

Markett Compositiion As Per Products


P

TH
HERAPEU
UTICS

VACCIN
NES

ANIIMAL HE
EALTH CA
ARE

FEE
ED ADDIITIVES

%A
AGE SHAR
RE OF DIF
FFERENT PRODUCT
P
T SEGMEN
NTS

25%
%

feeedadditives

55%
20%

v
vaccines
therapeutics

Sourcce: OPPI
Page|10
P

Animal Therapeutics And Diagnostics

The animal health industry is responsible for maintaining the health and productivity of the
over 3.3 billion livestock and 16 billion poultry worldwide, and ensuring the wholesomeness
and abundance of the food they produce. In addition, the industry must also cater to the health
and well being of companion animals. Despite this, the human healthcare market is 35 times
larger than the combined market for all nonhuman species. The reality is that the global
animal health market is very complex, operating under stringent and increasingly strict
regulations similar to those for human health, yet the market opportunities are considerably
smaller. In an increasingly risky environment for new product development, the difference
between success and failure in the future usually lies in successfully identifying the next
growth segment, developing the right product candidates, and being the first to market.
Despite all these risks, the industry continues to grow.
In contrast to human blockbuster-oriented pharmaceuticals, animal health is dominated by
large numbers of products with small revenues. Although there are hundreds of products
involved in this market, only about 20 products have sales exceeding $100 million per year.
However, the industry continues to forge on. The fastest growing therapeutic categories are in
the area of companion animals, specifically in the arthritis and pain segments of the market.

Antiparasitics In Animal Health IndustryCompanion animals and all of the major livestock species are exposed to challenge from a
broad range of parasites. Most compromise the health and wellbeing of animals directly,
while some present broader risks by acting as vectors for other pathogens. In livestock,
parasite infestations exert a major impact on levels of productivity and profitability. Losses
inflicted on producers at a global level run to many billions of dollars (liver fluke infestation
alone causes losses of an estimated $3 billion worldwide).
The main weapons available to farmers and companion animal owners in the fight against
parasites are chemotherapeutic drugs which either kill parasite populations or prevent the
development of immature parasites into adult forms. Parasites that survive the application of
these products are those with a natural tendency to resistance against the active ingredient or
class in question. Over time, this results in the development of resistant populations. Drugs
from different chemical classes are used in rotation programmes to slow the development of
Page|11

resistance, but the efficacy of some major antiparasitic groups against certain parasite species
has nevertheless declined significantly as a result of resistance. This is driving the search for
new chemical classes, and has also encouraged continued efforts to develop alternative
parasite control methods, including immunological approaches.
It has been a major source of growth in real terms over the past 10 years - due in large part to
the impact of new products commercialised in the companion animal ectoparasiticides
segment.
While new products have boosted values in the companion animal ectoparasiticides segment,
sales in other parts of the market have been affected by growing generic penetration of the
market. Ivermectin has been the most popular target for generic manufacturers since Merial's
patents on the molecule began to expire in major developed markets towards the end of the
1990s. Patents on several other leading antiparasitic brands have also expired during the past
five years, however, generic penetration of the antiparasitics market is set to increase further
through the remainder of this decade, as exclusivity periods for a number of other key
products reach an end.
With generic penetration expected to offset the impact of new drug launches in the sector,
increases in market value will be dependent largely on broad economic conditions and the
operating environment facing livestock producers in major markets. The further development
of existing products, through the application of formulation and delivery technologies or the
commercialisation of multi-ingredient treatments, will also help to bolster market values.
Real growth across the antiparasitic sector as a whole will be limited in most major markets,
however, and gains at global level are forecasted at a modest 2.5% a year, with sales expected
to total just under $5.3 billion in 2009.
Just as a relatively small number of major markets generate major shares of the total global
antiparasitic sales, so the sector is also dominated by a handful of companies. Merial alone
realises annual sales of more than $1.1 billion in the antiparasitics market, giving it a share in
the sector of almost 25%, while seven leading companies are responsible together for
approximately 62% of global antiparasitic product sales. While substantial shares of the
market are concentrated in the hands of a few market leaders, the antiparasitics sector is
becoming increasingly crowded as patents on major products expire. The range of companies
attempting to cash in on new generic opportunities is extremely broad, but a few specialist
generic manufacturers have emerged as major players in the sector.
Page|12

Animal Biotechnology: Technologies, Markets and Companies

Knowledge of animal genetics is important in the application of biotechnology to manage


genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are
also being applied to animal biotechnology. Biotechnology has potential applications in the
management of several animal diseases such as foot-and-mouth disease, classical swine
fever, avian flu and bovine spongiform encephalopathy. The most important biotechnologybased products consist of vaccines, particularly genetically engineered or DNA vaccines.
Gene therapy for diseases of pet animals is a fast developing area because many of the
technologies used in clinical trials humans were developed in animals and many of the
diseases of cats and dogs are similar to those in humans. RNA interference technology is now
being applied for research in veterinary medicine.

NutraceuticalsNutritional and dietary supplements - often named nutraceuticals as an amalgamation of the


terms nutritional and pharmaceutical - have come a long way since a new trend in the care of
companion animals emerged in the 1990s. This trend reflected a shift in the mindset of both
veterinarians and animal owners: rather than relying purely on medicinal products for the
prevention and treatment of diseases they started searching for nutritional and dietary
alternatives. Consequently, disease management was increasingly perceived as health
management, and the field of animal nutrition as such established itself as an important factor
in the achievement and maintenance of the well-being of animals.
Commercially available nutraceutical products for animals include the traditional substances
such as vitamins, minerals and amino acids, but also an increasing number of essential fatty
acids, antioxidants, probiotics, enzymes, and herbs. However, there has also been some
controversy regarding their safety and efficacy and it has been repeatedly suggested that they
should be classified as drugs.
New nutraceutical products for use in animals are in development, which mostly are spin-offs
from according research in the human field. Examples are fatty acid compounds for
applications in the joint health sector, compounds derived from mushrooms and novel
antioxidant substances. The development in the nutraceutical market sector has also had an
Page|13

impact on the pet food industry where manufacturers were able to identify a variety of
substances that could be employed in order to add value to their existing product lines, or to
develop new fortified food products.
There are generally three types of companies producing nutraceuticals for animals, the
dedicated nutraceutical manufacturers including herbal specialists, the pet food companies,
and the pharmaceutical manufacturers including both R&D-based and generic companies. All
these different types of companies have their different angles to access the new segment of
nutraceuticals for animals. While in the early stages of this industry sector, nutraceuticals for
animals were produced mainly by small-scale or niche manufacturers, both pharmaceutical
and nutritional companies have had an enter in this segment, with varying success. Those that
have managed to gain a stronghold in this market certainly have injected respectability, more
vigorous competition and technical knowledge into it.

Global Animal Health Market: Emerging Markets Driving GrowthThe animal health market is growing, albeit at a slower rate, in the recessionary economic
phase. Two factors are working in favour of the industry - pet owners' love for their
companion animals and the economic reasons for the treatment of livestock or farm animals.
The ""livestock"" segment, a high-volume market that represents around 57% of the
international animal health market is guided mostly by economic concerns as the market has
to meet the growing demand in protein requirements in developing countries. Increase in
demand for protein inevitably leads to increase in demand for food-producing animals.
Emerging markets such as Eastern Europe, Latin America and Asia are witnessing an
increase in share of the total pie of the animal health industry because of the increasing
importance given to animal health by the livestock breeders. As these regions are showing
very strong economic growth in the past few years, livestock breeders are giving due
importance to the better management of livestock to cater to the growing nutritional needs of
populations. But with various kinds of diseases reducing global animal production, animal
healthcare is gaining significant importance. Emerging economies thus offer significant
potential for animal health industry in the near future.

Page|14

The mature markets of North America and Western Europe, however, are supporting the
growth of animal health market as these regions are characterized by strong growth,
particularly in the ""companion animals"" sector.
The animal health market is highly concentrated, with the top nine players controlling more
than 80% of the total market. Recent acquisitions of Fort Dodge (Wyeth) by Pfizer and
Intervet by Schering-Plough have further consolidated the market.

Market Drivers
The reasons which have attracted different pharmaceutical industries to venture into animal
health care.

The robust growth pattern displayed by the poultry segment and the sheer size of the
cattle population has contributed largely to the growth of the animal health care
market.

The 2009 annual report of the International Federation for Animal Health (IFAH), a
global body representing manufacturers of animal health products, stated that global
demand for animal protein is expected to rise by 50% by 2020 as the animal
population grows, and as more households in emerging economies join the worlds
middle classes.

With increasing awareness about diseases that are spreading from unhealthy livestock
and poultry to humans like bird flu, livestock owners are showing increased interest to
ensure that their cattle are properly cared for. It is this growing awareness in emerging
economies like India that is attracting pharma companies.

Growing demand for new products and industry's investment in awareness of pet
owners. Although animal population has increased only marginally, the key driver for
growth is the willingness of owners to spend more on the health of their animals and
the ability of veterinarians to meet that need. The human-pet bond has a high
economic ceiling, and both veterinarians and the animal health industry have
recognised the potential of this market segment.

Emergence of new diseases.

Page|15

Change in animal production patterns and increase in productivity-Exposure to


international standards has brought about a heightened awareness of productivity and
best farm practices around the globe. Indian farmers are now conscious of the need to
increase profits by cutting costs and improving productivity levels. Animal health
products especially nutritional supplements have become important inputs to boost
productivity.

Ongoing food safety concerns-There is a growing awareness in the livestock industry


of the need for clean and healthy production. Many concepts like HACCP, clean milk
production and issues like antibiotic and pesticide residues have raised levels of
awareness. This has given a boost to the growth of the animal health care industry in
the country.

There are certain factors which can account as heyday for animal health care industry in
future:

Product development for certain segments like parasiticides for companion animals.

Increased shopping at retail outlets and through internet and over-the-counter (OTC)
products posing stiff competition to prescription.

Increased spending, better pet monitoring services, pet insurance, and owner lifestyles
will also shape the growth of the animal healthcare market.

Increasing professionalism of poultry industry.

Growth of organised dairy production and changing focus of farmers from treating to
preventing diseases.

Strategies To Tap Animal Health Care Industry


India's role as a leading milk producer has long been recognised at a global level and animal
health and management forms an inseparable element of the country's agronomy. Most often,
this has been the reason why pharmaceutical companies decided to foray into the animal
healthcare market. This focus has shaped market strategy, since the customer base was
mostly rural.
Accordingly, the animal healthcare industry focuses on aggressive promotion and marketing
strategies, emphasising animal health benefits.
Page|16

Concept Pharmaceuticals promotes their products through specialised and welltrained veterinary sales officers located in different parts of the country. Their strategy
is based on direct contact with consumers and indirect selling through veterinarians,
livestock supervisors etc organising farmer meetings in rural areas and selling
preventive vaccination and de-worming generates demand for our products through
these customers.

It is this growing awareness in emerging economies like India that is attracting


pharma companies. The only way to meet this enormous increase in demand is by
intensifying livestock production. But with disease currently reducing potential global
animal production by at least 20% a year, animal healthcare is gaining significant
importance.

Intas animal division has its own full-fledged marketing and sales strength, which
constantly inject promotion, techno-commercial services and awareness delivery to
veterinarians, dairy farmers and various rural based customer segments. provide wellappointed distribution network of chemists and dealers who smoothly disseminate the
entire product basket in urban, semi-urban, village towns and micro-interiors levels

Co-marketing efforts with milk co-operative societies and various NGOs also create a
vital channel that helps players penetrate the grass-root levels.

Customer segmentation based on products and wider coverage plans to call veterinary
doctors, associated paramedicals, trade channel partners and farmer meetings on
regular basis remains a key strategic essence to generate business

Challenges
The animal healthcare market faces challenges due to the fragmented nature of cattle
population and increasing distribution costs for animal health products. Stakeholders like
integrators in animal health business and established manufacturers of animal health
products, especially for the livestock segment, also pose challenges for pharmaceutical
companies who have animal health portfolios. Pharmaceutical companies who want to tap
veterinary markets, they may find it challenging because only the veterinary companies
would be able to provide enough resources in competitive markets. Patent expiration along
with pipeline products without ensured success, has created enormous pressure for big
players.
Page|17

Opportunities
A major portion of livestock population is devoid of effective veterinary services. India has a
pool of personnel with high managerial and technical competence along with skilled and
educated work force. Professional services are easily available. India has competitive
advantage in contract manufacturing due to- relative low cost of production availability of
raw material at competitive prices. It has a good network of world class education institutes
and established strengths in information and technology. Increase in the disposable income
both at rural and urban level is another impetus for the growing animal health care industry.
Changing lifestyle and increasing human- pet bond relationship where pharmaceutical
companies can cash upon. Indias commitment to free market economy and globalisation is
welcome opportunity for the multinational companies in the animal health care.

The OTC Animal Health Global Market Opportunity


Traditionally sales of animal health products have been via different retail channels, limited
by the regulatory classification of each specific product. Thus, products classified as being
suitable for "over-the-counter" (OTC) sales have been widely available across all outlets
(including pharmacies, veterinary clinics, supermarkets, and pet shops), while those restricted
to being only available with a prescription have been limited to distribution through the socalled "ethical" channel of either a vet clinic or a pharmacy.
The different retail outlets represent separate marketing channels, and historically certain
companies are predominantly active in particular channels. Reputations are built up over time
and once forged these commercial relationships can provide a large degree of inertia within
each channel of distribution. Companies are continually seeking new product opportunities.
One potential opportunity for increasing sales volume would be to expand the number of
pharmaceutical products available on the OTC market.
Given the inherent difficulty and expense of developing new compounds, the simplest route
is via the reclassification as OTC of pharmaceuticals formerly requiring prescriptions. This
would then allow a much greater distribution across the range of retail outlets.
The interplay of the different commercial forces within each distribution channel provides
barriers to potential new entrants. As products come to the end of their patent life and generic
Page|18

manufacturers seek to capitalise on the commercial opportunities of supplying a newly


available compound, the reclassification of an existing prescription veterinary medicine as an
OTC product offers additional commercial opportunities. The outcome of such repositioning
may be optimised by working in partnership with an established company within a particular
distribution channel.
In order to implement a successful strategy when considering repositioning a product from
the ethical to the OTC market, it is essential that insight into successful marketing is obtained
and the core elements of potentially winning tactics are recognised.

Outsourcing to Grow Exponentially


Large generics companies have challenged the patent holders very aggressively and several
blockbuster drugs have lost patent protection due to successful patent challenges. Declining
R&D productivity and increasing patent expiries, coupled with generics competition has led
to a significant increase in the total number of drugs under development. More drugs under
development would imply that MNCs would need to outsource more services and
intermediates from cost-efficient regions (including India).
India as a destination for outsourcing:
1. World-class quality at 30-40% lower cost.
2. Proven chemistry and process innovation skills instilled by years of fierce competition in
the domestic market.
3. India has six times the number of trained chemists as the US, available at a tenth of the
cost.
4. India has up to 40% lower capital cost, resulting in lower initial capex on new facilities.

Contract manufacturing the most scalable opportunity for Indian players


We believe that of the three broad outsourcing opportunities available to India CCS(current
cost to supplier), clinical trials and contract manufacturing, the most scalable business
opportunity for Indian players would be contract manufacturing. This is because:
Page|19

1) CCS
S would typically invollve supply of
o material at gram or kilogram leevel, while contract
manufaacturing invoolves supplies in tons.
2) CCS
S supplies are
a linked to
t the succcess of the partners R&D
R
pipeliine and aree, hence,
volatilee. Contract manufactur
m
ring suppliees, on the other
o
hand, are linked to the succcess of a
productt post comm
mercialisatioon and can provide rellatively stabble revenues (since pro
obability
of succeess post com
mmercialisaation is highher than thatt at the R&D
D level).

Key drrivers for ou


utsourcing (in %): Big Pharmacceutical Companies

lacckofcapacitiees
22

22
2
oth
hers

12

foccusoncoreco
ompetencies
44

lifeecyclemanaggement
tem
mprorarylackkof
cap
pacities

Surveey by: contrract pharmaa

Page|20
P

Mid/sm
mall sized pharmaceut
p
tical compaanies:

lacckofcapacitiees
22

22
2

12

oth
hers
foccusoncoreco
ompetencies

44

lifeecyclemanaggement
tem
mprorarylackkof
cap
pacities

Survey by:
b contractt pharma

Future
Extensiive rise in annimal healthhcare may mark
m
a good future forr this markeet. The pet and
a aqua
(fisheriees) segmentts are tomorrrow's markkets, while poultry
p
will remain at tthe centre of animal
health industry,
i
ass the functioonal foods market
m
is liikely to groow even in India. Therrefore in
India, growth
g
of poultry
p
and pet segmennts will disstinguish annimal healthhcare markeets from
other markets.
m
Thhough this market seeems to have high growth potenttial, it need
ds to be
tempereed with cauution. Potenntial in anim
mal health business
b
is always attaached to sensitivity
with coonsumers, policy
p
marrkers, healthhcare autho
orities and beneficiariies. Hence, animal
health industry
i
neeeds strategic directionn and navig
gation to coontinuouslyy grow and acquire
sizeablee market shaare.

Page|21
P